Given the evolution of GLP-1 receptor agonist drugs, the pharmacological harnessing of this ‘incretin effect’ that underpins meal-stimulated insulin secretion is an avenue that continues to be explored in the treatment of T2DM and obesity. Here, INS is linked to obesity disorder.